Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C.

Petta S, Handberg A, Marchesini G, Cammà C, Di Marco V, Cabibi D, Macaluso FS, Craxì A.

J Viral Hepat. 2013 Mar;20(3):174-82. doi: 10.1111/j.1365-2893.2012.01641.x. Epub 2012 Jul 9.

PMID:
23383656
2.

Increased soluble CD36 is linked to advanced steatosis in nonalcoholic fatty liver disease.

García-Monzón C, Lo Iacono O, Crespo J, Romero-Gómez M, García-Samaniego J, Fernández-Bermejo M, Domínguez-Díez A, Rodríguez de Cía J, Sáez A, Porrero JL, Vargas-Castrillón J, Chávez-Jiménez E, Soto-Fernández S, Díaz A, Gallego-Durán R, Madejón A, Miquilena-Colina ME.

Eur J Clin Invest. 2014 Jan;44(1):65-73. doi: 10.1111/eci.12192. Epub 2013 Nov 23.

PMID:
24134687
3.

Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis c virus genotype 1.

Petta S, Cammà C, Di Marco V, Alessi N, Barbaria F, Cabibi D, Caldarella R, Ciminnisi S, Licata A, Massenti MF, Mazzola A, Tarantino G, Marchesini G, Craxì A.

Hepatology. 2008 Jul;48(1):28-37. doi: 10.1002/hep.22316.

PMID:
18506842
4.

Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.

Soresi M, Tripi S, Franco V, Giannitrapani L, Alessandri A, Rappa F, Vuturo O, Montalto G.

Liver Int. 2006 Nov;26(9):1119-25.

PMID:
17032413
5.

Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C.

Harrison SA, Brunt EM, Qazi RA, Oliver DA, Neuschwander-Tetri BA, Di Bisceglie AM, Bacon BR.

Clin Gastroenterol Hepatol. 2005 Jun;3(6):604-9.

PMID:
15952103
6.

Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection.

Petta S, Macaluso FS, Cammà C, Marco VD, Cabibi D, Craxì A.

Liver Int. 2012 Oct;32(9):1443-50. doi: 10.1111/j.1478-3231.2012.02842.x. Epub 2012 Jul 5.

PMID:
22764879
7.

Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection.

Petta S, Cammà C, Di Marco V, Cabibi D, Ciminnisi S, Caldarella R, Licata A, Massenti MF, Marchesini G, Craxì A.

Antivir Ther. 2009;14(5):631-9.

PMID:
19704165
8.

Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1.

Petta S, Amato M, Cabibi D, Cammà C, Di Marco V, Giordano C, Galluzzo A, Craxì A.

Hepatology. 2010 Nov;52(5):1543-52. doi: 10.1002/hep.23859.

PMID:
20799355
9.

Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C.

Thomopoulos KC, Theocharis GJ, Tsamantas AC, Siagris D, Dimitropoulou D, Gogos CA, Labropoulou-Karatza C.

Eur J Gastroenterol Hepatol. 2005 Feb;17(2):149-53.

PMID:
15674091
10.

TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1.

Petta S, Di Marco V, Di Stefano R, Cabibi D, Cammà C, Marchesini G, Craxì A.

J Viral Hepat. 2011 Jul;18(7):e372-80. doi: 10.1111/j.1365-2893.2011.01439.x. Epub 2011 Feb 22.

PMID:
21692950
11.
12.

Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.

Zografos TA, Liaskos C, Rigopoulou EI, Togousidis E, Makaritsis K, Germenis A, Dalekos GN.

Am J Gastroenterol. 2008 Mar;103(3):605-14. doi: 10.1111/j.1572-0241.2007.01729.x. Epub 2008 Jan 8.

PMID:
18190648
13.

Influence of steatosis on progression of fibrosis and virological response in chronic hepatitis C cases.

Rafi H, Kabbaj N, Salihoun M, Amrani L, Acharki M, Guedira M, Nya M, Amrani N.

Arab J Gastroenterol. 2011 Sep;12(3):136-8. doi: 10.1016/j.ajg.2011.07.003. Epub 2011 Sep 15.

PMID:
22055591
14.

The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients.

Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallée M, Heaton S, Conrad A, Pockros PJ, McHutchison JG.

J Hepatol. 2004 Mar;40(3):484-90.

PMID:
15123364
15.

Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection.

Petta S, Cammà C, Di Marco V, Alessi N, Cabibi D, Caldarella R, Licata A, Massenti F, Tarantino G, Marchesini G, Craxì A.

Am J Gastroenterol. 2008 May;103(5):1136-44. doi: 10.1111/j.1572-0241.2008.01813.x.

PMID:
18477344
16.

Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C.

Cammà C, Bruno S, Di Marco V, Di Bona D, Rumi M, Vinci M, Rebucci C, Cividini A, Pizzolanti G, Minola E, Mondelli MU, Colombo M, Pinzello G, Craxì A.

Hepatology. 2006 Jan;43(1):64-71.

PMID:
16374856
17.

Steatosis as a predictive factor for treatment response in patients with chronic hepatitis C.

Antúnez I, Aponte N, Fernández-Carbia A, Rodríguez-Perez F, Toro DH.

P R Health Sci J. 2004 Jun;23(2 Suppl):57-60.

PMID:
16929588
18.

Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population.

Handberg A, Højlund K, Gastaldelli A, Flyvbjerg A, Dekker JM, Petrie J, Piatti P, Beck-Nielsen H; RISC Investigators.

J Intern Med. 2012 Mar;271(3):294-304. doi: 10.1111/j.1365-2796.2011.02442.x. Epub 2011 Sep 14.

19.

Analysis of the sustained virological response in patients with chronic hepatitis C and liver steatosis.

Piccoli Lde Z, Mattos AA, Coral GP, Mattos AZ, Santos DE.

Arq Gastroenterol. 2011 Jul-Sep;48(3):179-85.

20.

Correlation of serum adiponectin levels and hepatic steatosis in hepatitis C virus genotype 1 infection.

Kara B, Gunesacar R, Doran F, Kara IO, Akkiz H.

Adv Ther. 2007 Sep-Oct;24(5):972-82.

PMID:
18029322

Supplemental Content

Support Center